ArticleJournal of gastrointestinal oncology2026
Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The impact of concurrent metabolic dysfunction associated steatotic liver disease (MASLD) on the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy is controversial. Moreover, there is little information regarding the effect of metabolic burden on HCC patients. This study aimed to identify the influence of concurrent MASLD and metabolic burden on the prognosis of HCC patients after hepatectomy. Methods: Data of HCC patients who received hepatectomy between 2013 and 2018 at West China Hospital were retrospectively reviewed. Metabolic burden was defined as the cumulative number of metabolic abnormalities including overweight/obesity, blood hypertension, prediabetes/diabetes and dyslipidemia [including hypertriglyceridemia and/or low high-density lipoprotein cholesterol (HDL-C)]. Logistic regression and Cox regression analyses were carried out to identify the independent risk factors associated with severe postoperative complications and oncological outcomes respectively. Results: After propensity score matching (PSM), severe postoperative complication rates were 5.4% and 6.9% in MASLD and non-MASLD patients, respectively (P=0.54). Moreover, both the 5-year recurrence-free survival (RFS) and overall survival (OS) rates of MASLD and non-MASLD patients were similar (RFS: 44.7% Conclusions: The metabolic burden, but not MASLD, adversely affects the prognosis of HCC patients after hepatectomy. The more metabolic burden patients have, the more likely they are to have a poor prognosis after hepatectomy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.